DSP-107 News - LARVOL Sigma

|||||||||| DSP-107 / Kahr Medical, Tecentriq (atezolizumab) / Roche
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting fusion protein, in combination with atezolizumab in patients with advanced solid tumors. (On Demand | Hall A; Poster Bd # 474) - Apr 26, 2023 - Abstract #ASCO2023ASCO_2397;
P1/2
These Phase 1 data suggest that the combination of DSP107 with PD(L)1 blockade may have anti-tumor activity in cold tumors such as MSS-CRC. Clinical trial information: NCT04440735.

||||||||||  DSP-107 / Kahr Medical
Trial completion date, Trial primary completion date, Combination therapy, Monotherapy, Metastases:  A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Apr 26, 2023
P1/2, N=125, Recruiting,  Sponsor: Kahr Medical
Clinical trial information: NCT04440735. Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Sep 2024

||||||||||  DSP-107 / Kahr Medical
Trial completion date, Trial primary completion date:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (clinicaltrials.gov) -  Mar 13, 2023
P1, N=36, Recruiting,  Sponsor: Kahr Medical
Trial completion date: Aug 2023 --> Dec 2024 | Trial primary completion date: Jun 2023 --> Sep 2024 Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Aug 2024

|||||||||| DSP-107 / Kahr Medical
Phase 1 dose escalation study of DSP107, a first-in-class CD47 and 4-1BB targeting multifunctional immune-recruitment protein, in patients with advanced solid tumors. (Available On Demand; 301) - Apr 28, 2022 - Abstract #ASCO2022ASCO_1706;
P1/2
Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Dec 2022 --> Aug 2024 DSP107 is a novel, CD47 and 4-1BB targeting fusion protein with a differentiated safety, binding and pharmacodynamic profile compared to other CD47 and 4-1BB targeting agents.

|||||||||| DSP-107 / Kahr Medical
Journal: DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity. (Pubmed Central) - Mar 31, 2022
DSP107 is a novel, CD47 and 4-1BB targeting fusion protein with a differentiated safety, binding and pharmacodynamic profile compared to other CD47 and 4-1BB targeting agents. DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients.

||||||||||  DSP-107 / Kahr Medical
Enrollment open:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (clinicaltrials.gov) -  Feb 10, 2022
P1, N=36, Recruiting,  Sponsor: Kahr Medical
DSP107 effectively (re)activated innate and adaptive anticancer immune responses and may be of therapeutic use alone and in combination with rituximab for the treatment of DLBCL patients. Not yet recruiting --> Recruiting

||||||||||  DSP-107 / Kahr Medical
Trial initiation date:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (clinicaltrials.gov) -  Jan 4, 2022
P1, N=36, Not yet recruiting,  Sponsor: Kahr Medical
Not yet recruiting --> Recruiting Initiation date: Oct 2021 --> Jan 2022

||||||||||  DSP-107 / Kahr Medical
Phase classification:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (clinicaltrials.gov) -  Sep 2, 2021
P1, N=36, Not yet recruiting,  Sponsor: Kahr Medical
Initiation date: Oct 2021 --> Jan 2022 Phase classification: P1/2 --> P1

||||||||||  DSP-107 / Kahr Medical
New P1 trial, New P1/2 trial:  A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies (clinicaltrials.gov) -  Jun 23, 2021
P1/2, N=36, Not yet recruiting,  Sponsor: Kahr Medical

||||||||||  DSP-107 / Kahr Medical
Enrollment open, Combination therapy, Monotherapy, Metastases:  A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Nov 9, 2020
P1/2, N=100, Recruiting,  Sponsor: Kahr Medical
Phase classification: P1/2 --> P1 Not yet recruiting --> Recruiting

|||||||||| dihomo gamma linolenic acid (DS107 oral) / DS Biopharma, DSP107 / Kahr Medical, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] DSP107, a Novel Bi-Functional Fusion Protein That Combines Inhibition of CD47 with Targeted Activation of 4-1BB to Trigger Innate and Adaptive Anticancer Immune Responses (Channel 7 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_1505;
Moreover, binding of DSP107 to CD47 enables the 4-1BBL-mediated costimulation of antitumor T cell cytotoxicity. Thus, DSP107 activates both innate and adaptive anticancer immunity and may be of use for the treatment of DLBCL alone or in combination with RTX.

|||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono, Herceptin (trastuzumab) / Roche, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells () - Aug 15, 2020 - Abstract #ITOCI2020ITOC-I_81;
DSP107 is a first-in-class drug candidate that can be used as a monotherapy or in combination with tumor-targeting monoclonal antibodies to trigger induction of anti-cancer immunity. DSP107 is currently tested in IND-enabling studies and clinical development is planned to commence in 2020.

||||||||||  DSP-107 / Kahr Medical
New P1/2 trial, Combination therapy, Monotherapy, Metastases:  A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors (clinicaltrials.gov) -  Jun 22, 2020
P1/2, N=100, Not yet recruiting,  Sponsor: Kahr Medical

|||||||||| DSP107 / Kahr Medical
DSP107—a first in class, bifunctional fusion protein targeting both innate and adaptive immunity (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1057;
In vivo, DSP107 was efficacious as monotherapy and in combination with anti PD-L1. Doses <= 50 mg/kg were safe and well tolerated in monkeys.



	Diseases Companies Products Productz Mechanisms of Action Sites